A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Stopped Insufficient clinical benefit to participants at the selected recommended phase 2 (RP2D) dose in Part A.

Conditions

• Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

Interventions

• DRUG: TAK-164
• DRUG: 89Zr-TAK-164

Sponsor

Millennium Pharmaceuticals, Inc.